Survey finds strong veterinary support for stem cell therapy

A new survey from the American Animal Hospital Association and Gallant suggests broad veterinary optimism about stem cell therapy for inflammatory disease in pets. In the survey of more than 1,000 veterinary professionals, 95% said stem cell therapy will become a standard treatment option within the next decade, while nearly 93% said they’d be more likely to offer regenerative therapy if it were available off the shelf and delivered through a simple IV protocol. Respondents also said current therapies often fall short of addressing underlying disease, with about 87% agreeing that today’s options primarily manage symptoms rather than root causes. (gallant.com)

Why it matters: For veterinary professionals, the findings point to a market and practice environment that may be increasingly receptive to regulated regenerative products, especially for chronic inflammatory conditions with limited durable options. That interest is landing as Gallant pushes one of the field’s highest-profile candidates, an off-the-shelf allogeneic mesenchymal stromal cell therapy for refractory feline chronic gingivostomatitis, through FDA’s conditional approval pathway. Gallant has said the product was targeting early 2026 for conditional approval after receiving a “technical section complete” letter on reasonable expectation of effectiveness, and FDA says conditional approval allows legal marketing after a sponsor shows safety and a reasonable expectation of effectiveness, though not yet full proof of effectiveness. (dvm360.com)

What to watch: Watch whether enthusiasm translates into adoption as the first FDA-reviewed veterinary MSC products near market, especially in indications like refractory FCGS where Gallant has reported clinical field data showing quality-of-life improvement in 79% of treated cats by Day 90. (gallant.com)